tobramycin
- Prasco
-
300 mg/4 mLsolution
-
66993-195-9411-digit: 66993-0195-9456 ampules, 4 mL each
-
Source: FDA, updated October 30, 2026
Generic name: tobramycin
Used for: Pseudomonas lung infection in cystic fibrosis
Ask for the cash price
Generic tobramycin
No pharmacy we check posts a price for it.
A regular generic has the same active ingredient as Bethkis, and the FDA requires it to work the same way.
Details for each option
We didn’t find a savings card or cash price from Bethkis’s maker. Ask the pharmacy for Bethkis’s cash price. With insurance, ask what your plan charges.
The same medicine as Bethkis, without the brand name. Give the pharmacy its NDC to get it.
tobramycin
Source: FDA, updated October 30, 2026
“Before you fill my Bethkis, can you tell me what I’d pay for the brand, for the authorized generic from Prasco (NDC 66993-195-94), and for a regular generic?”
Paying cash? Ask for each one’s cash price. With insurance, ask what your plan charges for each.
Official labels and ingredient lists from DailyMed (U.S. National Library of Medicine).
Same active and inactive ingredients as Bethkis.
Active: tobramycin 300 mg/4 mL
Inactive, on both labels:
One company sells a generic of Bethkis that the FDA rates a substitute. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.
It’s mostly filled by specialty pharmacies. Your prescriber’s office or insurer can tell you which one to use.
Made by Mankind Pharma
Product page on northstarrxllc.com
300 mg/4 mL
| Package | NDC |
|---|---|
| Carton of 224 mL | 72603-630-56 |
Inactive ingredients: sodium chloride, sulfuric acid, water, sodium hydroxide
Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.
BETHKIS is an inhaled aminoglycoside antibacterial indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of six years, patients with a forced expiratory volume in one second (FEV1) less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia.
Source: the FDA label for Bethkis (Chiesi USA, Inc.), February 24, 2023. Full label on DailyMed
Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/bethkis/